High Expectations From EU’s ‘Neutral’ Hub On Real-World Evidence
The Netherlands-based GetReal Institute builds on seven years of multi-stakeholder collaboration to promote greater understanding of real-world evidence.
You may also be interested in...
The EU's Innovative Medicines Initiative (IMI) is about to launch a new collaborative public-private project looking at how best to co-ordinate and support activities being conducted in the area of adaptive pathways, with a view to producing a comprehensive plan for developing and using relevant tools and methodologies throughout the product life cycle.
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
Companies can get the European Medicines Agency’s scientific opinion for their products’ use in EU and non-EU countries at about the same time.